Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 27;14(8):1562-1575.
doi: 10.4254/wjh.v14.i8.1562.

Assessment of circulating levels of microRNA-326, microRNA-424, and microRNA-511 as biomarkers for hepatocellular carcinoma in Egyptians

Samar Samir Youssef  1 , Asmaa Elfiky  2 , Mohamed M Nabeel  3 , Hend Ibrahim Shousha  3 , Tamer Elbaz  3 , Dalia Omran  4 , Mohammad Saeed Marie  3 , Mohammad A Elzahry  4 , Amr Abul-Fotouh  4 , Ahmed Hashem  4 , Mohamed F Guda  5 , Ashraf O Abdelaziz  3
Affiliations

Assessment of circulating levels of microRNA-326, microRNA-424, and microRNA-511 as biomarkers for hepatocellular carcinoma in Egyptians

Samar Samir Youssef et al. World J Hepatol. .

Abstract

Background: Hepatocellular carcinoma (HCC) is the fifth most common cancer. Differential expression of microRNAs (miRNAs)-326, miRNA-424, and miRNA-511 has been associated with the diagnosis and prognosis of HCC in different populations. However, limited information is available regarding their expression in Egyptian HCC patients.

Aim: To assess the role of circulating miRNAs-326, miRNA-424, and miRNA-511 in Egyptian HCC patients.

Methods: This prospective observational study included 70 HCC patients and 25 healthy controls. The circulating levels of these three miRNAs were evaluated by real-time PCR. Receiver operating characteristic curve analysis was used to test the diagnostic accuracy of microRNA expression levels.

Results: All miRNAs were differentially expressed in HCC patients; miRNAs326 and miRNA-424 were upregulated, while miRNA-511 was downregulated. Both miRNA-326 and miRNA-424 showed sensitivity and specificity of 97%, 71.4%, and 52%, 60%, respectively, to differentiate HCC from controls. Moreover, miRNA-326 was associated with survival and could differentiate between Child grades (A vs B); miRNA-424 significantly differentiated early vs intermediate stages of HCC; while miRNA-511 was significantly correlated with response to modified Response Evaluation Criteria in Solid Tumors (mRECIST).

Conclusion: We conclude that miRNA-326, miRNA-424, and miRNA-511 have diagnostic and prognostic roles in Egyptian patients with hepatitis C virus-related HCC and should be considered for better disease management.

Keywords: Hepatocellular carcinoma; Modified response evaluation criteria in solid tumors; miRNA-424; miRNA-511; miRNAs-326.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: The authors declare no competing interests.

Figures

Figure 1
Figure 1
Receiver operating characteristic curve of the studied miRNAs.
Figure 2
Figure 2
Survival curve among the studied parameters. A: Survival curve in relation to stage; B: Survival curve in relation to response to treatment according to mRECIST; C: Survival curve in relation to miRNA-326.
See this image and copyright information in PMC

References

    1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–E386. - PubMed
    1. Astarci HM, Özyalvaçli G, Sertçelik A. Karaciğerin primer ve metastatik karsinomlarının ayrımında pCEA, mCEA, AFP ve CK19'un tanısal değeri. Abant Tıp Dergisi. 2019;5:39–46.
    1. Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7:6. - PubMed
    1. McGuire S. World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015. Adv Nutr. 2016;7:418–419. - PMC - PubMed
    1. Baek KK, Kim JH, Uhm JE, Park SH, Lee J, Park JO, Park YS, Kang WK, Lim HY. Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective comparison with previously known prognostic models. Oncology. 2011;80:167–174. - PubMed